Search hospitals > Illinois > Dekalb
Northwestern Medicine Cancer Center Kishwaukee
Claim this profileDekalb, Illinois 60115
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Lymphoma
Conducts research for Lung Cancer
102 reported clinical trials
45 medical researchers
Summary
Northwestern Medicine Cancer Center Kishwaukee is a medical facility located in Dekalb, Illinois. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lymphoma, Lung Cancer and other specialties. Northwestern Medicine Cancer Center Kishwaukee is involved with conducting 102 clinical trials across 256 conditions. There are 45 research doctors associated with this hospital, such as Aparna Kalyan, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
HER2 positive
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Aparna KalyanNorthwestern University1 year of reported clinical research
Expert in Cancer
Studies Bile Duct Cancer
20 reported clinical trials
39 drugs studied
Sunandana ChandraNorthwestern University1 year of reported clinical research
Expert in Melanoma
Expert in Skin Cancer
22 reported clinical trials
31 drugs studied
Devalingam Mahalingam, MBBChBAONorthwestern University5 years of reported clinical research
Studies Solid Tumors
Studies Tumors
17 reported clinical trials
53 drugs studied
Jochen H. Lorch, M.D.Northwestern University3 years of reported clinical research
Studies Cancer
Studies Squamous Cell Carcinoma
15 reported clinical trials
25 drugs studied
Clinical Trials running at Northwestern Medicine Cancer Center Kishwaukee
Breast Cancer
Esophageal Adenocarcinoma
Cancer
Prostate Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Carcinoma
Lung Cancer
Renal Cell Carcinoma
Diffuse Large B-Cell Lymphoma
Non-Small Cell Lung Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Northwestern Medicine Cancer Center Kishwaukee?
Northwestern Medicine Cancer Center Kishwaukee is a medical facility located in Dekalb, Illinois. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lymphoma, Lung Cancer and other specialties. Northwestern Medicine Cancer Center Kishwaukee is involved with conducting 102 clinical trials across 256 conditions. There are 45 research doctors associated with this hospital, such as Aparna Kalyan, Sunandana Chandra, Devalingam Mahalingam, MBBChBAO, and Jochen H. Lorch, M.D..